文献速递妇科

卵巢癌患者对PARP抑制剂维持治疗的偏好研究

Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
PubMed 文献 · Gynecol Oncol · 2020-01-22

该离散选择实验调查了95名卵巢癌女性对PARP抑制剂维持治疗在生存获益、不良反应、MDS/AML死亡风险及月自付费用等方面的偏好。结果显示患者最看重总生存期和月费用,愿意为2.2个月OS获益接受5%的MDS/AML死亡风险,并需3-4个月PFS获益才愿承受轻度不良反应。

要点

  • 患者最看重总生存期获益与月自付费用,其次为MDS/AML死亡风险。
  • 可接受5%MDS/AML死亡风险以换取2.2个月OS或4.8个月PFS获益。
  • 需2.6个月PFS获益才接受轻度疲乏,需4.4个月才接受轻度恶心。

核心结论

  • 卵巢癌患者考虑维持治疗时最受总生存期获益驱动。
  • 患者期望至少3-4个月PFS获益才愿承受轻度治疗不良反应。

研究设计与样本

  • 离散选择实验,纳入95名符合条件的卵巢癌女性完成调查。
  • 评估6个属性:OS、PFS、恶心、疲乏、MDS/AML死亡概率、月自付费用。
  • 采用随机参数logit回归建模选择与属性水平的关系。

主要发现

  • 平均年龄62岁,48%有复发,17%曾使用过PARP抑制剂。
  • OS平均重要性权重24.5/100,月费用24.6,MDS/AML死亡风险17.9,恶心14.7,PFS10.5,疲乏7.8。
  • 可接受5%MDS/AML死亡风险以换取2.2个月额外OS或4.8个月PFS。
  • 需2.6个月PFS增益才接受轻度治疗相关疲乏,需4.4个月才接受轻度恶心。

临床怎么用

  • 与卵巢癌患者讨论PARP抑制剂维持治疗时,应重点沟通OS获益与月自付费用。
  • 告知患者轻度不良反应需以约3-4个月PFS获益为代价,辅助共同决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To measure preferences of women with ovarian cancer regarding risks, side effects, costs and benefits afforded by maintenance therapy (MT) with a poly ADP ribose polymerase (PARP) inhibitor. METHODS: A discrete-choice experiment elicited preferences of women with ovarian cancer regarding 6 attributes (levels in parentheses) relevant to decisions for MT versus treatment break: (1) overall survival (OS; 36, 38, 42 months); (2) progression-free survival (PFS; 15, 17, 21 months); (3) nausea (none, mild, moderate); (4) fatigue (none, mild, moderate); (5) probability of death from myelodysplastic syndrome/acute myelogenous leukemia (MDS/AML; 0% to 10%); (6) monthly out-of-pocket cost ($0 to $1000). Participants chose between 2 variable MT scenarios and a static scenario representing treatment break, with multiple iterations. Random-parameters logit regression was applied to model choices as a function of attribute levels. RESULTS: 95 eligible participants completed the survey; mean age was 62, 48% had recurrence, and 17% were ever-PARP inhibitor users. Participants valued OS (average importance weight 24.5 out of 100) and monthly costs (24.6) most highly, followed by risk of death from MDS/AML (17.9), nausea (14.7), PFS (10.5) and fatigue (7.8). Participants would accept 5% risk of MDS/AML if treatment provided 2.2 months additional OS or 4.8 months PFS. Participants would require gains of 2.6 months PFS to accept mild treatment-related fatigue and 4.4 months to accept mild nausea. CONCLUSIONS: When considering MT, women with ovarian cancer are most motivated by gains in OS. Women expect at least 3-4 months of PFS benefit to bear mild side effects of treatment.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Havrilesky LJ, Lim S, Ehrisman JA, et al. Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. Gynecol Oncol. 2020. PMID: 31982178. doi:10.1016/j.ygyno.2020.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。